We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NEW TAX LEGISLATION IN U.S. HOUSE OFFERS INCENTIVES FOR DEVICE GROWTH

NEW TAX LEGISLATION IN U.S. HOUSE OFFERS INCENTIVES FOR DEVICE GROWTH

May 4, 2006

New legislation to change the tax code should help medical device and biotech companies more easily attract and access funding while investing in R&D.

Introduced by Rep. Melissa Hart (R-Pa.) in the House Committee on Ways and Means, the "U.S. Healthcare Technologies Competitiveness Act of 2006" (HR 5115) would amend the Internal Revenue Code of 1986 to "modernize the tax treatment of biomedical research organizations." The bill is cosponsored by Reps. Philip English (R-Pa.) and Gerald Weller (R-Ill.)

The legislation seeks to update tax laws to eliminate investment disincentives and, if passed, would go into effect after Dec. 31.

"We applaud Representative Hart for introducing this important piece of legislation that will modernize U.S. tax laws. Her bill will help medical technology companies to more easily attract the capital they need to continue their work on behalf of patients and physicians in developing the next generation of lifesaving and life-enhancing innovations," said Stephen Ubl, president and CEO of industry association AdvaMed, April 7.

"This bill will eliminate disincentives in current tax laws that inhibit investment in medical technology companies and threaten America's position as the global leader in this vital sector," said Ubl.

The legislation lists two sections of provisions, one relating to corporate tax incentives and the other to investor tax incentives. ()a href="http://www.fdanews.com/ddl/33_18/" target=_blank>

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • UKflag.jpg

    UK Study Says Single Shot of Pfizer/BioNTech Vaccine Significantly Lessened Asymptomatic Infections

  • emergency use authorization approved

    Eurofins Receives FDA Emergency Authorization for Over-the-Counter COVID-19 Test

  • FDA clears text

    Vetex Medical’s Thrombectomy Catheter Cleared by FDA

  • 100Bills_flatmoney.gif

    Merck Purchases Rights to Debiopharm’s Xevinapant for More Than $1 Billion

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing